XXXX media in Sweden. Role of @entity6729 and the rationale for choice of antimicrobial therapy.

@entity1 @entity6729 @entity697
The occurrence of @entity6729 in the nasopharynx and middle ear exudate was investigated in 3 studies. Bacteria were isolated from the nasopharynx in 63% of 180 healthy @entity1 and @entity6729 , the most common bacterium present, was isolated in 36%. In 75 @entity1 with primary @entity697 , bacteria were isolated from the nasopharynx in 98% and from the middle ear exudate in 80%. @entity6729 was found in the nasopharynx in 43% and in the middle ear exudate in pure culture in 9%. In those @entity1 in whom @entity6729 was isolated from the middle ear exudate it was also present in the nasopharynx. In 420 @entity1 , 338 with primary @entity697 and 82 who relapsed or did not respond to previous antibiotic therapy, @entity6729 was isolated from the nasopharynx in approximately 50%. About half of the @entity6729 strains were beta-lactamase-producing and the majority of these strains were isolated in @entity1 under 3 years of age. Of @entity1 with primary @entity697 who had beta-lactamase-producing @entity6729 about 50% had not previously received antibiotic treatment. @entity6729 is commonly found in the nasopharynx of healthy @entity1 as well as in @entity1 with @entity697 . Many of the strains are beta-lactamase-producing though many of the @entity1 have not been previously treated with antibiotics. In middle ear exudate, @entity6729 is found in about 10% of cases.(ABSTRACT TRUNCATED AT 250 WORDS)
